Drug Database
PA

parathyroid hormone (Natpara / NPSP558 / SHP634)

✓ Approved

AstraZeneca UK Limited · PTH1R · Recombinant Proteins

What is parathyroid hormone?

parathyroid hormone is a recombinant proteins developed by AstraZeneca UK Limited. It is approved for therapeutic indications via injectable (others) or subcutaneous injection.

Drug Profile

Brand NamesNatpara, NPSP558, SHP634
CompanyAstraZeneca UK Limited
Drug ClassRecombinant Proteins
Molecular TargetPTH1R
RouteInjectable (Others), Subcutaneous Injection
StatusApproved
Sources: ClinicalTrials.gov, AstraZeneca UK Limited

Mechanism of Action

Molecular Targets

parathyroid hormone acts on 1 molecular target:

PTH1Rparathyroid hormone 1 receptor (PTHR, EKNS)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

parathyroid hormone is developed for 2 unique indications across 2 therapeutic areas.

Therapeutic AreaConditionPhase
Endocrine disordersHypoparathyroidism✓ Approved
Musculoskeletal and connective tissue disordersOsteoporosis✓ Approved

Related Research Articles

PubMedThe Laryngoscope2026-09-19

Visual Parathyroid Identification in Thyroidectomy: A Decision Curve Analysis of Gland Preservation.

Pithuksurachai Paveena P, Pongsapich Warut W, Triprateepsilp Noppadon N, Chongkolwatana Cheerasook C et al.

To evaluate the clinical utility and net benefit of intraoperative visual identification for parathyroid preservation during thyroidectomy using decision curve analysis (DCA). Suspected parathyroid tissues (n = 50) were identified intraoperatively by junior staff and residents and photographed for independent consensus review by three expert otolaryngologists. Fine-needle aspiration parathyroid hormone washout (electrochemiluminescence immunoassay; ≥ 100 pg/mL) served as the surrogate biochemical reference standard. Diagnostic performance was assessed using contingency tables, logistic regression, receiver operating characteristic analysis, and DCA. Expert visual identification achieved 84.0% sensitivity, 44.0% specificity, and 64.0% accuracy. Positive predictive values were 60.0% for experts, 51.5% for junior staff, and 47.1% for residents (p = 0.632). Logistic regression yielded odds ratios of 1.69 for experts (p = 0.380) and 1.20 for junior staff (p = 0.765); model AUC was 0.56. DCA showed greater net benefit than "Treat All" and "Treat None" strategies at a clinically relevant threshold probability of 27%. Visual identification demonstrates limited diagnostic accuracy that did not differ significantly across experience levels, although this comparison is constrained by differing assessment conditions. The low specificity underscores the need for objective adjunctive confirmation and supports evaluating biochemical and optical adjuncts in future prospective studies.

PMID 42760592
Read full article →
PubMedFrontiers in endocrinology2026-09-19

Case Report: Reopening the anabolic window - romosozumab added to ongoing denosumab for severe osteoporosis in two kidney transplant recipients.

Barbuto Simona S, Mastromauro Paolo P, Zavatta Guido G, Vetrano Daniele D et al.

Kidney transplant recipients develop disorders of mineral and bone metabolism that further impair bone strength, leading to osteoporosis and a high fracture risk. However, evidence in this setting is limited. Romosozumab, a sclerostin inhibitor with both anabolic and antiresorptive effects, is an attractive option, but its use in transplant recipients, as well as its combination with denosumab, has rarely been reported. We describe two female kidney transplant recipients with severe osteoporosis and persistently high fracture risk despite long-term denosumab, in whom romosozumab (210 mg monthly) was added to ongoing denosumab for 12 months. In both patients the bone-formation markers P1NP and BAP rose early, and bone mineral density improved preferentially at the lumbar spine (Case 1 + 5.9%, Case 2 + 11.2%), with only modest changes at the femoral neck and total hip. Serum calcium, parathyroid hormone, 25-hydroxyvitamin D and allograft function remained stable throughout, with no clinically significant hypocalcemia, and neither patient sustained a new vertebral fracture. Adding romosozumab to ongoing denosumab thus reopened the anabolic window and improved lumbar-spine bone mineral density without compromising mineral metabolism or graft function. This combination may represent a reasonable option for carefully selected transplant recipients who continue to lose bone or to fracture despite antiresorptive therapy, pending confirmation in controlled studies.

PMID 42761068
Read full article →
PubMedFrontiers in plant science2026-09-19

Drip fertigation technique with planting models strategies trigger grain filling, endogenous hormonal changes and maize productivity under semi-arid regions.

Wang Jiaqi J, Diao Jian J, Xu Zhe Z, Ma Ning N et al.

Mulch drip fertigation strategies have been widely adopted to improve maize productivity in semi-arid regions. However, the impact of the mulch-based drip fertigation on endogenous hormone dynamics in crops and grain yield has not been fully elucidated, and the biochemical mechanisms underlying yield improvement under different drip fertigation strategies remain unclear. Grain filling has a significant impact on maize production. The aim of this study was to explore the effect of plastic film mulching materials on maize grain filling under a drip fertigation strategy, and the relationship between this effect and changes in endogenous hormones. This study compared biodegradable film mulching (BM) with soil crust ridges (SR) under high (H), medium (M), and low (L) drip irrigation conditions, and measured that the grain filling characteristics and changes in grain endogenous hormones in various parts of maize ears during the growth stage. The results showed that the grain filling rate, dry matter plant-1, hormone changes, yield components, water use efficiency (WUE), and ET of maize under the BMH treatment were significantly higher than those under the SR treatment. BMH treatment significantly increased soil water storage significantly increased plant hormone contents such as abscisic acid (ABA), indole-3-Acetic acid (IAA), and zeatin + Zeatin Riboside (Z+ZR), and decreased the evolution rate of gibberellins (Gas) and ethylene, thereby increasing maize yield. These results indicate that BMH treatment improved the filling process, soil respiration rate, WUE, yield, and yield composition of maize. High drip fertigation with BM or SR treatment significantly affected endogenous hormone changes, thereby regulating the activity grain-filling period (AGP), maximum grain-filling rate (Gmax), maximum grain weight (Wmax), mean grain-filling rates (Gmean) and occurrence time of maximal filling rate (Tmax) of maize. In addition, high drip fertigation and the BM strategy significantly increased soil water storage and soil respiration rate during the grain filling period. Based on these results, we conclude that BMH significantly improved soil water storage, thereby regulating the maize grain filling rate, which was significantly correlated with the balance of endogenous hormones in the grains.

PMID 42760979
Read full article →
PubMedFrontiers in endocrinology2026-09-19

Amniotic-fluid metabolomics identifies phospholipid remodeling as a metabolic signature of intrauterine exposure in pregnancies with polycystic ovary syndrome.

Wu Shimin S, Shi Jiayu J, He Chenyan C, Chen Jie J et al.

Polycystic ovary syndrome is associated with metabolic and hormonal disturbances during pregnancy, but whether these alterations are reflected in the fetal intrauterine exposure environment remains incompletely understood. This study aimed to identify polycystic ovary syndrome-related intrauterine metabolic signatures using late-gestation amniotic fluid. Untargeted metabolomic profiling was performed on late-gestation amniotic fluid samples from women with polycystic ovary syndrome and controls. Differential metabolite analysis, pathway-level analysis, and multilevel sensitivity analyses were conducted to identify robust metabolic alterations associated with maternal polycystic ovary syndrome. Exploratory placental transcriptomic analysis and targeted RT-qPCR assessment in an independent sample set were further used to examine tissue-level molecular changes related to the lipidomic findings. Amniotic fluid from pregnancies with polycystic ovary syndrome showed a distinct metabolic profile dominated by lipid remodeling. Differential metabolites were mainly enriched in membrane phospholipids, sphingolipid-related metabolites, polyunsaturated fatty acid-related pathways, and selected steroid hormone-related metabolites. Phospholipid remodeling was characterized by decreased phosphatidylcholine species, increased phosphatidylethanolamine species, a lower phosphatidylcholine/phosphatidylethanolamine ratio, and redistribution of arachidonic acid-containing phospholipids. Alpha-linolenic acid metabolism provided an additional polyunsaturated fatty acid-related signal. Sphingolipid enrichment suggested that lipid alterations extended from membrane structural remodeling to lipid-mediated signaling. Selected steroid hormone-related metabolites were also elevated, consistent with an altered hormonal milieu in pregnancies with polycystic ovary syndrome. These signatures remained largely stable across sensitivity analyses, as did the multivariable-adjusted inverse association between PE(16:0/20:4) and birth weight. Exploratory placental transcriptomic analysis and targeted RT-qPCR assessment in a small independent cohort provided preliminary tissue-level support for phospholipid-related molecular alterations, with the clearest changes involving PLA2-family genes and PCYT1A, suggesting cross-cohort convergence at the pathway level. These findings identify phospholipid remodeling as a major amniotic-fluid metabolic signature of polycystic ovary syndrome-related intrauterine exposure. PUFA-related metabolism, sphingolipid enrichment, and steroid hormone-related alterations provide additional metabolic context. Complementary placental molecular findings and the inverse association between PE(16:0/20:4) and birth weight further suggest potential links with the maternal-fetal interface and fetal growth. Further studies are needed to clarify the biological relevance of these changes and their potential role in offspring metabolic susceptibility.

PMID 42760943
Read full article →
PubMedJournal of biophotonics2026-09-19

Enhancement of Harvested Islet Functionality Through Photostimulation.

Fowlds Kelli K, Darden Carly M CM, Lawrence Michael C MC, Cho Michael M

Allogeneic islet transplantation is a promising treatment for Type I diabetes, but its success is limited by islet loss during isolation, purification, and engraftment, resulting in variable long-term insulin independence. Our previous studies demonstrated that photobiomodulation (PBM) significantly enhances insulin and glucagon secretion in pancreatic cells, likely through modulation of ATP production and calcium signaling pathways involved in hormone release. Building on these mechanistic findings, we investigated whether PBM could similarly improve the functionality of whole islets before transplantation. Mouse islets were isolated by pancreatectomy, cultured ex vivo, and treated daily with PBM for 7 days. Fluorescence imaging and functional assays were used to assess insulin expression and secretion. PBM significantly enhanced insulin secretion, with an approximately twofold increase observed after 3 days of treatment. These findings support PBM as a promising, noninvasive approach for improving islet function before transplantation.

PMID 42760903
Read full article →
PubMedPflugers Archiv : European journal of physiology2026-09-19

High-salt diet modulates endocrine regulation between cortisol and FGF23.

Moor Matthias B MB, Sagmeister Michael S MS, Crastin Ana A, Kopper Klaudia K et al.

Excessive dietary salt intake is a global health concern, affecting cardiovascular, renal, and bone health. While the renin-angiotensin-aldosterone system (RAAS) is a known regulator of dietary salt-induced hormonal responses, the impact of adrenal cortisol remains unclear. Here, we performed a retrospective analysis in individuals (n = 321) consuming a random diet. Dietary salt intake positively correlated with urinary cortisol and inversely correlated with plasma fibroblast growth factor 23 (FGF23), a bone-derived hormone regulating phosphate and vitamin D homeostasis. Controlled salt diets in healthy individuals confirmed a dose-dependent increase in urinary cortisol and suppression of plasma FGF23. In mice, oral corticosterone, a cortisol analogue, reduced circulating FGF23 levels. RNA-seq analysis of corticosterone-treated MC3T3 osteoblasts identified suppression of FGF23 via glucocorticoid receptor activation, anti-inflammatory pathways, and reduced osteoblast activity. Our findings provide evidence for an endocrine cascade in which high salt intake elevates cortisol signaling and suppresses FGF23.

PMID 42760427
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about parathyroid hormone